DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study

Luca Bello, Lauren P. Morgenroth, Heather Gordish-Dressman, Eric P. Hoffman, Craig M McDonald, Sebahattin Cirak

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Objective: To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations in a large, prospective natural history study of Duchenne muscular dystrophy (DMD), with particular attention to mutations amenable to emerging molecular treatments. Methods: We analyzed data from the Cooperative International Neuromuscular Research Group Duchenne Natural History Study for participants with DMD single- or multi-exon deletions or duplications with defined exon boundaries (n 186), or small mutations identified by sequencing (n 26, including 16 nonsense point mutations). We performed a time-to-event analysis of LoA, a strong indicator of overall disease severity, adjusting for glucocorticoid treatment and genetic modifiers. Results: Participants with deletions amenable to skipping of exon 44 had later LoA (median 14.8 years, hazard ratio 0.31, 95% confidence interval 0.14-0.69, p 0.004). Age at LoA did not differ significantly in participants with deletions amenable to exon 45, 51, and 53 skipping, duplications, and small rearrangements. Nonsense mutation DMD also showed a typical median age at LoA (11.1 years), with a few outliers (ambulatory around or after 16 years of age) carrying stop codons within in-frame exons, more often situated in the rod domain. Conclusions: As exon 44 skipping-amenable DMD has a later LoA, mutation-specific randomization and selection of placebo groups are essential for the success of clinical trials.

Original languageEnglish (US)
Pages (from-to)401-409
Number of pages9
JournalNeurology
Volume87
Issue number4
DOIs
StatePublished - Jul 26 2016

Fingerprint

Duchenne Muscular Dystrophy
Natural History
Walking
Exons
Genotype
Mutation
Nonsense Codon
Terminator Codon
Random Allocation
Point Mutation
Glucocorticoids
Placebos
Clinical Trials
Confidence Intervals
Therapeutics
Research
Genes

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Bello, L., Morgenroth, L. P., Gordish-Dressman, H., Hoffman, E. P., McDonald, C. M., & Cirak, S. (2016). DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. Neurology, 87(4), 401-409. https://doi.org/10.1212/WNL.0000000000002891

DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. / Bello, Luca; Morgenroth, Lauren P.; Gordish-Dressman, Heather; Hoffman, Eric P.; McDonald, Craig M; Cirak, Sebahattin.

In: Neurology, Vol. 87, No. 4, 26.07.2016, p. 401-409.

Research output: Contribution to journalArticle

Bello, L, Morgenroth, LP, Gordish-Dressman, H, Hoffman, EP, McDonald, CM & Cirak, S 2016, 'DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study', Neurology, vol. 87, no. 4, pp. 401-409. https://doi.org/10.1212/WNL.0000000000002891
Bello, Luca ; Morgenroth, Lauren P. ; Gordish-Dressman, Heather ; Hoffman, Eric P. ; McDonald, Craig M ; Cirak, Sebahattin. / DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study. In: Neurology. 2016 ; Vol. 87, No. 4. pp. 401-409.
@article{c93f3dacbf2a40a0b1daa28a7fa433a8,
title = "DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study",
abstract = "Objective: To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations in a large, prospective natural history study of Duchenne muscular dystrophy (DMD), with particular attention to mutations amenable to emerging molecular treatments. Methods: We analyzed data from the Cooperative International Neuromuscular Research Group Duchenne Natural History Study for participants with DMD single- or multi-exon deletions or duplications with defined exon boundaries (n 186), or small mutations identified by sequencing (n 26, including 16 nonsense point mutations). We performed a time-to-event analysis of LoA, a strong indicator of overall disease severity, adjusting for glucocorticoid treatment and genetic modifiers. Results: Participants with deletions amenable to skipping of exon 44 had later LoA (median 14.8 years, hazard ratio 0.31, 95{\%} confidence interval 0.14-0.69, p 0.004). Age at LoA did not differ significantly in participants with deletions amenable to exon 45, 51, and 53 skipping, duplications, and small rearrangements. Nonsense mutation DMD also showed a typical median age at LoA (11.1 years), with a few outliers (ambulatory around or after 16 years of age) carrying stop codons within in-frame exons, more often situated in the rod domain. Conclusions: As exon 44 skipping-amenable DMD has a later LoA, mutation-specific randomization and selection of placebo groups are essential for the success of clinical trials.",
author = "Luca Bello and Morgenroth, {Lauren P.} and Heather Gordish-Dressman and Hoffman, {Eric P.} and McDonald, {Craig M} and Sebahattin Cirak",
year = "2016",
month = "7",
day = "26",
doi = "10.1212/WNL.0000000000002891",
language = "English (US)",
volume = "87",
pages = "401--409",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study

AU - Bello, Luca

AU - Morgenroth, Lauren P.

AU - Gordish-Dressman, Heather

AU - Hoffman, Eric P.

AU - McDonald, Craig M

AU - Cirak, Sebahattin

PY - 2016/7/26

Y1 - 2016/7/26

N2 - Objective: To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations in a large, prospective natural history study of Duchenne muscular dystrophy (DMD), with particular attention to mutations amenable to emerging molecular treatments. Methods: We analyzed data from the Cooperative International Neuromuscular Research Group Duchenne Natural History Study for participants with DMD single- or multi-exon deletions or duplications with defined exon boundaries (n 186), or small mutations identified by sequencing (n 26, including 16 nonsense point mutations). We performed a time-to-event analysis of LoA, a strong indicator of overall disease severity, adjusting for glucocorticoid treatment and genetic modifiers. Results: Participants with deletions amenable to skipping of exon 44 had later LoA (median 14.8 years, hazard ratio 0.31, 95% confidence interval 0.14-0.69, p 0.004). Age at LoA did not differ significantly in participants with deletions amenable to exon 45, 51, and 53 skipping, duplications, and small rearrangements. Nonsense mutation DMD also showed a typical median age at LoA (11.1 years), with a few outliers (ambulatory around or after 16 years of age) carrying stop codons within in-frame exons, more often situated in the rod domain. Conclusions: As exon 44 skipping-amenable DMD has a later LoA, mutation-specific randomization and selection of placebo groups are essential for the success of clinical trials.

AB - Objective: To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations in a large, prospective natural history study of Duchenne muscular dystrophy (DMD), with particular attention to mutations amenable to emerging molecular treatments. Methods: We analyzed data from the Cooperative International Neuromuscular Research Group Duchenne Natural History Study for participants with DMD single- or multi-exon deletions or duplications with defined exon boundaries (n 186), or small mutations identified by sequencing (n 26, including 16 nonsense point mutations). We performed a time-to-event analysis of LoA, a strong indicator of overall disease severity, adjusting for glucocorticoid treatment and genetic modifiers. Results: Participants with deletions amenable to skipping of exon 44 had later LoA (median 14.8 years, hazard ratio 0.31, 95% confidence interval 0.14-0.69, p 0.004). Age at LoA did not differ significantly in participants with deletions amenable to exon 45, 51, and 53 skipping, duplications, and small rearrangements. Nonsense mutation DMD also showed a typical median age at LoA (11.1 years), with a few outliers (ambulatory around or after 16 years of age) carrying stop codons within in-frame exons, more often situated in the rod domain. Conclusions: As exon 44 skipping-amenable DMD has a later LoA, mutation-specific randomization and selection of placebo groups are essential for the success of clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84980315837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84980315837&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000002891

DO - 10.1212/WNL.0000000000002891

M3 - Article

C2 - 27343068

AN - SCOPUS:84980315837

VL - 87

SP - 401

EP - 409

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 4

ER -